September 19, 2017, Vol 318, No. 11, Pages 979-1080
Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections
Jonathan Kimmelman, PhD; Benjamin Carlisle, MA; Mithat Gönen, PhD
JAMA. 2017;318(11):1003-1004. doi:10.1001/jama.2017.11502
This Viewpoint discusses the drug development portfolio—a family of trials assessing a drug for different indications or in different combinations with other drugs—and summarizes some of the challenges drug portfolios pose for policy, care, and human protections.